Menu

All Activities

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

Attention Pharmacists and Pharmacy Techs: Click to access CPE Monitor and latest CE information More Information

Featured Activity

This activity will cover key topics of interest to stakeholders who set practice policy and will be called upon to evaluate and make decisions on issues pertaining to biosimilars.

Find an Activity

Find an Activity

Find an Activity

Choose from the criteria below to find an activity that fits you best.

SHOW SEARCH

Atopic Dermatitis: A Specialty Pharmacy 360-Degree View of the Patient

 

A 1-hour CE satellite symposium to be held at the National Association of Specialty Pharmacy 2017 Annual Meeting and Educational Conference

Wednesday, September 20, 2017, 7:00 - 8:00 AM
Marriott Wardman Park, Washington, DC

For more information and to register for the NASP Annual Meeting, please click here 

Activity Description

With the advent of new agents for Atopic Dermatitis (AD) moving through specialty pharmacy channels, specialty pharmacists are suddenly at the hub of stakeholders in the treatment of AD. This activity will provide an overview of AD, including an introduction to the impact of inadequately treated moderate-to-severe disease and details of current and emerging therapies. The ways in which specialty pharmacists can work as part of multidisciplinary AD teams, actively engage in shared decision-making with patients, and reduce treatment barriers to increase value will be highlighted.

Learning Objectives

The target audience for this activity is pharmacists interested in or practicing in Specialty Pharmacy. After completing the activity, participants should be able to:

  • Describe the impact of moderate-to-severe atopic dermatitis on quality of life and productivity
  • Distinguish the mechanism of action of current and emerging treatments for moderate-to-severe atopic dermatitis
  • Differentiate current and emerging treatments for moderate-to-severe atopic dermatitis based on efficacy, safety, and monitoring requirements
  • Delineate strategies specialty pharmacy can use to support appropriate use and adherence to therapies for moderate-to-severe atopic dermatitis

Agenda

7:00 – 8:00 AM CE Activity
To attend this symposium, you must be registered for the NASP meeting.

Faculty

Speaker: Steven A. Scott, Pharm.D.
Associate Professor
Department of Pharmacy Practice
Purdue University College of Pharmacy
West Lafayette, Indiana

Moderator: Laura Jester, PharmD
Pharmacist, PBM Specialty Pharmacy Programs
Navitus Health Solutions
Madison, Wisconsin

CE Accreditation

Pharmacists

ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-0000-17-347-L01-P has been assigned to this live knowledge-based activity (initial release date 9-20-2017). This activity is approved for 1.0 contact hour (0.10 CEU) in states that recognize ACPE providers. The activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation no later than October 20, 2017 to receive pharmacy CE credit. Statements of completion will be issued online at www.ProCE.com and proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.

Disclosure

It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. Faculty disclosure will be announced prior to the presentation. A portion of grant funds received by ProCE from Sanofi Genzyme and Regeneron Pharmaceuticals will be used to compensate the faculty for this presentation.

Please note: The opinions expressed in this activity should not be construed as those of the CE provider. The information and views presented in this activity are those of the faculty through clinical practice and knowledge of the professional literature. Portions of this activity may include the use of drugs and/or devices for unlabeled indications, which should be considered experimental. Participants are advised to consult manufacturer product information and the professional literature, and use professional judgment in applying the presented information in patient-care activities.

Funding

This CE activity is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

For more information and to register for the NASP Annual Meeting, please click here 

The material presented in this CE activity does not reflect the views of ProCE, Inc. or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.